The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer

Metastatic prostate cancer, which shows progression despite castration testosterone levels, was previously defined as hormone-refractory. This definition has recently been changed to the one presently used – castrate-resistant prostate cancer. Numerous fundamental studies have provided evidence that...

Descripción completa

Detalles Bibliográficos
Autores principales: Milecki, Tomasz, Antczak, Andrzej, Kwias, Zbigniew, Milecki, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068814/
https://www.ncbi.nlm.nih.gov/pubmed/24966789
http://dx.doi.org/10.5114/wo.2014.42723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068814/
https://www.ncbi.nlm.nih.gov/pubmed/24966789
http://dx.doi.org/10.5114/wo.2014.42723

Ejemplares similares